Weakness in vaccine division driving CSL lower

Morgans Financial Limited

CSL has been considerably weaker following its FY16 results announced 3 weeks ago (down c7%, after being down c5% on the day of its earnings release). So what gives? Well, recall FY16 underlying results were broadly in line with expectations, with solid growth across the core plasma businesses (c80% of total sales) and stable margins. However, there were two items the market focused on it clearly did not like (and still doesn't): Weakness in the newly branded Seqirus vaccine division (c15% of total sales), which reported a NPAT loss of US$206m on the back of a soft flu season and recent Novartis acquisition, stripping nearly 10% out of earnings; FY17 earnings outlook calling for NPATg c11%, below consensus expectations c19%. So it looks like share weakness is merely a case of the jilted lover(s)…use weakness to accumulate.


Morgans Financial Limited

Morgans is Australia's largest national full-service retail stockbroking and wealth management firm, with more than 300,000 clients, 500 authorised representatives and 850 staff, operating from offices in all states and territories. As well as...

Expertise

No areas of expertise

ASX:CSL

Comments

Please sign in to comment on this wire.